|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Barbieri CE, Bangma CH, Bjartell A, Catto
JW, Culig Z, Grönberg H, Luo J, Visakorpi T and Rubin MA: The
mutational landscape of prostate cancer. Eur Urol. 64:567–576.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cuzick J, Thorat MA, Andriole G, Brawley
OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, et
al: Prevention and early detection of prostate cancer. Lancet
Oncol. 15:e484–e492. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Khandrika L, Kumar B, Koul S, Maroni P and
Koul HK: Oxidative stress in prostate cancer. Cancer Lett.
282:125–136. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wiseman H and Halliwell B: Damage to DNA
by reactive oxygen and nitrogen species: Role in inflammatory
disease and progression to cancer. Biochem J. 313:17–29. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Finkel T: Signal transduction by
mitochondrial oxidants. J Biol Chem. 287:4434–4440. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Janssen-Heininger YM, Mossman BT, Heintz
NH, Forman HJ, Kalyanaraman B, Finkel T, Stamler JS, Rhee SG and
van der Vliet A: Redox-based regulation of signal transduction:
Principles, pitfalls, and promises. Free Radic Biol Med. 45:1–17.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cairns RA, Harris IS and Mak TW:
Regulation of cancer cell metabolism. Nat Rev Cancer. 11:85–95.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pantziarka P, Bouche G, Meheus L, Sukhatme
V and Sukhatme VP: Repurposing Drugs in Oncology (ReDO)-mebendazole
as an anti-cancer agent. ecancermedicalscience. 8:2014. View Article : Google Scholar
|
|
11
|
Armando RG, Mengual Gómez DL and Gomez DE:
New drugs are not enough drug repositioning in oncology: An update.
Int J Oncol. 56:651–684. 2020.PubMed/NCBI
|
|
12
|
Rushworth LK, Hewit K, Munnings-Tomes S,
Somani S, James D, Shanks E, Dufès C, Straube A, Patel R and Leung
HY: Repurposing screen identifies mebendazole as a clinical
candidate to synergise with docetaxel for prostate cancer
treatment. Br J Cancer. 122:517–527. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Horton J: Albendazole: A broad spectrum
anthelminthic for treatment of individuals and populations. Curr
Opin Infect Dis. 15:599–608. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li QZ, Hao YH, Gao XJ, Gao WX and Bing Z:
The target of benzimidazole carbamate against cysticerci
cellulosae. Agric Sci China. 6:1009–1017. 2007. View Article : Google Scholar
|
|
15
|
Xiao SH, Feng JJ, Guo HF, Jiao PY, Yao MY
and Jiao W: Effects of mebendazole, albendazole, and praziquantel
on fumarate hydratase, pyruvate kinase, and phosphoenolpyruvate
carboxykinase of Echinococcus granulosus cyst wall harbored in
mice. Zhongguo Yao Li Xue Bao. 15:69–72. 1994.PubMed/NCBI
|
|
16
|
Zhou F, Du J and Wang J: Albendazole
inhibits HIF-1α-dependent glycolysis and VEGF expression in
non-small cell lung cancer cells. Mol Cell Biochem. 428:171–178.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pourgholami MH, Cai ZY, Wang L, Badar S,
Links M and Morris DL: Inhibition of cell proliferation, vascular
endothelial growth factor and tumor growth by albendazole. Cancer
Invest. 27:171–177. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pourgholami MH, Cai ZY, Badar S, Wangoo K,
Poruchynsky MS and Morris DL: Potent inhibition of tumoral
hypoxia-inducible factor 1α by albendazole. BMC Cancer. 10:1432010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pourgholami MH, Khachigian LM, Fahmy RG,
Badar S, Wang L, Chu SW and Morris DL: Albendazole inhibits
endothelial cell migration, tube formation, vasopermeability, VEGF
receptor-2 expression and suppresses retinal neovascularization in
ROP model of angiogenesis. Biochem Biophys Res Commun. 397:729–734.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang LJ, Lee YC, Huang CH, Shi YJ, Chen
YJ, Pei SN, Chou YW and Chang LS: Non-mitotic effect of albendazole
triggers apoptosis of human leukemia cells via SIRT3/ROS/p38
MAPK/TTP axis-mediated TNF-α upregulation. Biochem Pharmacol.
162:154–168. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pourgholami MH, Woon L, Almajd R, Akhter
J, Bowery P and Morris DL: In vitro and in vivo suppression of
growth of hepatocellular carcinoma cells by albendazole. Cancer
Lett. 165:43–49. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kang BS, Choi JS, Lee SE, Lee JK, Kim TH,
Jang WS, Tunsirikongkon A, Kim JK and Park JS: Enhancing the in
vitro anticancer activity of albendazole incorporated into
chitosan-coated PLGA nanoparticles. Carbohydr Polym. 159:39–47.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Choi EK, Kim SW, Nam EJ, Paek J, Yim GW,
Kang MH and Kim YT: Differential effect of intraperitoneal
albendazole and paclitaxel on ascites formation and expression of
vascular endothelial growth factor in ovarian cancer cell-bearing
athymic nude mice. Reprod Sci. 18:763–771. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liang J, Li R, He Y, Ling C, Wang Q, Huang
Y, Qin J, Lu W and Wang J: A novel tumor-targeting treatment
strategy uses energy restriction via co-delivery of albendazole and
nanosilver. Nano Res. 11:4507–4523. 2018. View Article : Google Scholar
|
|
25
|
Zhang X, Zhao J, Gao X, Pei D and Gao C:
Anthelmintic drug albendazole arrests human gastric cancer cells at
the mitotic phase and induces apoptosis. Exp Ther Med. 13:595–603.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ghasemi F, Black M, Vizeacoumar F, Pinto
N, Ruicci KM, Le CCSH, Lowerison MR, Leong HS, Yoo J, Fung K, et
al: Repurposing Albendazole: New potential as a chemotherapeutic
agent with preferential activity against HPV-negative head and neck
squamous cell cancer. Oncotarget. 8:71512–71519. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ehteda A, Galettis P, Pillai K and Morris
DL: Combination of albendazole and 2-methoxyestradiol significantly
improves the survival of HCT-116 tumor-bearing nude mice. BMC
Cancer. 13:862013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guzmán C, Bagga M, Kaur A, Westermarck J
and Abankwa D: ColonyArea: An ImageJ plugin to automatically
quantify colony formation in clonogenic assays. PLoS One.
9:e924442014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liang CC, Park AY and Guan JL: In vitro
scratch assay: A convenient and inexpensive method for analysis of
cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCT method. methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
D'Autréaux B and Toledano MB: ROS as
signalling molecules: Mechanisms that generate specificity in ROS
homeostasis. Nat Rev Mol Cell Biol. 8:813–824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Marengo B, Nitti M, Furfaro AL, Colla R,
Ciucis CD, Marinari UM, Pronzato MA, Traverso N and Domenicotti C:
Redox homeostasis and cellular antioxidant systems: Crucial players
in cancer growth and therapy. Oxid Med Cell Longev.
2016:62356412016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li SM, Chen CH, Chen YW, Yen YC, Fang WT,
Tsai FY, Chang JL, Shen YY, Huang SF, Chuu CP, et al: Upregulation
of CISD2 augments ROS homeostasis and contributes to tumorigenesis
and poor prognosis of lung adenocarcinoma. Sci Rep. 7:118932017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Galanis A, Pappa A, Giannakakis A, Lanitis
E, Dangaj D and Sandaltzopoulos R: Reactive oxygen species and
HIF-1 signalling in cancer. Cancer Lett. 266:12–20. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Korswagen HC: Regulation of the
Wnt/β-catenin pathway by redox signaling. Dev Cell. 10:687–688.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang G, Huang Y-X, Zhang R, Hou LD, Liu H,
Chen XY, Zhu JS and Zhang J: Toosendanin suppresses oncogenic
phenotypes of human gastric carcinoma SGC 7901 cells partly via miR
200a mediated downregulation of β-catenin pathway. Int J Oncol.
51:1563–1573. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ravindranath A, Yuen HF, Chan KK, Grills
C, Fennell DA, Lappin TR and El-Tanani M: Wnt-β-catenin-Tcf-4
signalling-modulated invasiveness is dependent on osteopontin
expression in breast cancer. Br J Cancer. 105:542–551. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kypta RM and Waxman J: Wnt/β-catenin
signalling in prostate cancer. Nat Rev Urol. 9:418–428. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zheng H, Jia L, Liu C-C, Rong Z, Zhong L,
Yang L, Chen XF, Fryer JD, Wang X, Zhang YW, et al: TREM2 promotes
microglial survival by activating Wnt/β-catenin pathway. J
Neurosci. 37:1772–1784. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Carley DW: Drug repurposing: identify,
develop and commercialize new uses for existing or abandoned drugs.
Part II. IDrugs. 8:3102005.PubMed/NCBI
|
|
41
|
Carley DW: Drug repurposing: identify,
develop and commercialize new uses for existing or abandoned drugs.
Part I. IDrugs. 8:3062005.PubMed/NCBI
|
|
42
|
Castro LS, Kviecinski MR, Ourique F,
Parisotto EB, Grinevicius VM, Correia JF, Wilhelm Filho D and
Pedrosa RC: Albendazole as a promising molecule for tumor control.
Redox Biol. 10:90–99. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xiao D, Powolny AA, Moura MB, Kelley EE,
Bommareddy A, Kim SH, Hahm ER, Normolle D, Van Houten B and Singh
SV: Phenethyl isothiocyanate inhibits oxidative phosphorylation to
trigger reactive oxygen species-mediated death of human prostate
cancer cells. J Biol Chem. 285:26558–26569. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sun R, Meng X and Pu Y, Sun F, Man Z,
Zhang J, Yin L and Pu Y: Overexpression of HIF-1a could partially
protect K562 cells from 1,4-benzoquinone induced toxicity by
inhibiting ROS, apoptosis and enhancing glycolysis. Toxicol In
Vitro. 55:18–23. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Traverso N, Ricciarelli R, Nitti M,
Marengo B, Furfaro AL, Pronzato MA, Marinari UM and Domenicotti C:
Role of glutathione in cancer progression and chemoresistance.
Oxidative medicine and cellular longevity. 2013:9729132013.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tang L, Fang W, Lin J, Li J, Wu W and Xu
J: Vitamin D protects human melanocytes against oxidative damage by
activation of Wnt/β-catenin signaling. Lab Invest. 98:1527–1537.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Khalilzadeh A, Wangoo KT, Morris DL and
Pourgholami MH: Epothilone-paclitaxel resistant leukemic cells
CEM/dEpoB300 are sensitive to albendazole: Involvement of apoptotic
pathways. Biochem Pharmacol. 74:407–414. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Peehl DM: Primary cell cultures as models
of prostate cancer development. Endocr Relat Cancer. 12:19–47.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Greenberg NM, DeMayo F, Finegold MJ,
Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik
RJ and Rosen JM: Prostate cancer in a transgenic mouse. Proc Natl
Acad Sci USA. 92:3439–3443. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Gingrich JR, Barrios RJ, Morton RA, Boyce
BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM and Greenberg
NM: Metastatic prostate cancer in a transgenic mouse. Cancer Res.
56:4096–4102. 1996.PubMed/NCBI
|
